Duchenne Muscular Dystrophy (DMD)
X-Linked Recessive Progressive Myopathic Degeneration
Primary risk age: Toddlerhood through Young Adulthood (Symptoms present between 2 to 5 years; affects boys)
- Urgency
- Severe
- Typical age
- Toddlerhood through Young Adulthood (Symptoms present between 2 to 5 years; affects boys)
- Body system
- Musculoskeletal System
Typical course: This is a progressive, terminal genetic disorder without a cure; management is continuous and lifelong.
Reviewed against AAP · CDC · WHO · NHS guidance Last reviewed 2026-06-13
1. Summary & Pathophysiology
X-Linked Recessive Progressive Myopathic Degeneration
Pathophysiology (Development Path)
Dystrophin acts as a structural anchor that connects the muscle fiber cytoskeleton to the extracellular matrix, protecting the membrane during muscle contraction. Without dystrophin, muscle contraction leads to membrane tears and calcium influx. This triggers cellular necrosis and progressive loss of muscle fibers, which are replaced by fat and fibrous tissue.
Primary Causes & Etiology
A mutation in the DMD gene on the X chromosome, leading to a complete absence of the dystrophin protein.
2. Symptom Continuum
- Early Onset Signs
Delay in walking milestones, frequent falls, difficulty running or climbing stairs, and a clumsy, waddling gait.
- Progressive Phase
Gower's Sign (the child must "climb up" his own legs with his hands to stand up, indicating proximal muscle weakness). Pseudohypertrophy of the calves (enlargement due to fat infiltration).
- Severe Indicators
Loss of independent ambulation by age 12, requiring a wheelchair. Progressive scoliosis, cardiomyopathy, and respiratory muscle weakness leading to respiratory failure in the late teens or twenties.
3. Clinical Verification
Markedly elevated Serum Creatine Kinase (CK) levels (often 10 to 100 times normal). Diagnosis is confirmed by genetic testing showing a DMD gene deletion or mutation.
4. Care & Elements Plan
Primary Care Treatment Plan
Supportive and palliative care. Initiate daily oral corticosteroids to delay the loss of strength and prolong ambulation. Provide physical therapy, orthotics, cardiac monitoring, and respiratory support (BiPAP) as the disease progresses.
Home Support Elements
Perform regular gentle stretching exercises to prevent joint contractures. Ensure a safe home layout to prevent falls, and provide nutritional support to manage weight and prevent obesity.
Generic Active Ingredients (No Brands)
- Prednisone or Deflazacort (oral corticosteroid active ingredients used to slow muscle degeneration and prolong ambulation).
Lists active elements only. Never administer self-designed therapies.
5. Doctor Critical Lines
Critical Thresholds: When to See a Doctor
Seek pediatric evaluation if a toddler exhibits frequent falls, has large calf muscles but struggles to run, or uses his hands on his thighs to stand up.
6. Vaccine & Prevention
Routine Prophylaxis (Prevention)
Genetic counseling for families with a history of DMD; carrier detection for mothers of affected boys.
Immunization Context
Children should receive all routine immunizations, including annual influenza and pneumococcal vaccines, to prevent respiratory infections.
7. Timelines & Outlook
Active Timeline
This is a progressive, terminal genetic disorder without a cure; management is continuous and lifelong.
Expected Prognosis
Progressive and life-shortening. With modern multidisciplinary care, life expectancy has extended into the late twenties or early thirties.
Potential Untreated Complications
Loss of mobility, severe joint contractures, scoliosis, dilated cardiomyopathy, respiratory failure, and swallowing difficulties.
More in Inflammatory, Autoimmune & Degenerative Myopathies
Moderate Juvenile Idiopathic Arthritis (JIA)
Chronic Pediatric Autoimmune Inflammatory Arthritis
Toddlerhood through Adolescence (Onset before 16 years; varies by subtype)
Moderate Transient Synovitis of the Hip
Acute Self-Limiting Joint Synovial Inflammation
3 to 8 Years (Most common cause of pediatric hip pain)
Severe Osteomyelitis
Acute Hematogenous Metaphyseal Osteomyelitis
3 to 12 Years (Peak pediatric age)